本文選題：阿德福韋酯　切入點：乙型肝炎　出處：《中國社區(qū)醫(yī)師》2016年35期 　論文類型：期刊論文

【摘要】：目的:觀察阿德福韋酯治療慢性乙型肝炎患者的病毒載量變化及不良反應(yīng)。方法:第一階段(第0~24周)對照組予多烯磷膽堿酯膠囊,治療組予阿德福韋酯;第二階段(第25~48周)兩組用藥進行交換,于治療24周、48周觀察HBV-DNA變化。結(jié)果:24周時,治療組和對照組HBV-DNA中位數(shù)較基線水平均有下降;48周時,對照組中位數(shù)較基線水平下降2.4 log10拷貝/m L,治療組HBV-DNA中位數(shù)恢復(fù)到基線水平。藥物可能相關(guān)的不良事件大多為輕中度,兩組腎功能無明顯變化。結(jié)論:阿德福韋酯常規(guī)劑量,能有效抑制病毒復(fù)制,具有良好的耐受性和安全性。
[Abstract]:Objective: to observe the changes of viral load and adverse reactions in patients with chronic hepatitis B treated with adefovir dipivoxil. In the second stage (25 ~ 48 weeks), the two groups were used to exchange drugs. The changes of HBV-DNA were observed at 24 weeks after treatment and 48 weeks after treatment. Results at the end of 24 weeks, the median HBV-DNA of the treatment group and the control group were decreased from the baseline level to 48 weeks. The median of control group was decreased by 2.4 log10 copy / mL compared with the baseline level, and the median of HBV-DNA returned to baseline level in the treatment group. Most of the possible adverse events related to drugs were mild to moderate, and there was no significant change in renal function between the two groups. Conclusion: the routine dose of adefovir ester, It can effectively inhibit virus replication and has good tolerance and safety.
【作者單位】： 商丘市第一人民醫(yī)院;
【分類號】：R512.62
，

本文編號：1645246